RxDoctor Payments Data

Daniel Rodriguez, MD

Family Medicine · Trinity, FLNPI 1356331995

Payments from drug & device makers

$182,587in general payments, 2019–2025

Across 338 payments — averaging $540.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$133K
  • Pfizer$20K
  • GSK$16K
  • Kowa Research Institute, Inc.$8K
  • Teva Pharmaceuticals USA, Inc.$856
  • Lilly USA, LLC$696
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$5,548100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$182,587 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$93,887
Medicare patients
228
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$143,726
MounjaroTirzepatide61$77,245
JardianceEmpagliflozin57$62,736
JanuviaSitagliptin Phosphate69$59,555
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$59,322
EliquisApixaban107$55,964
FarxigaDapagliflozin Propanediol33$36,767
RybelsusSemaglutide15$25,147
XareltoRivaroxaban37$22,423
TradjentaLinagliptin27$17,949
Breo ElliptaFluticasone/Vilanterol24$11,726
Repatha PushtronexEvolocumab12$10,682
LinzessLinaclotide13$7,538
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,378
SynjardyEmpagliflozin/Metformin Hcl24$7,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$613$168,873142 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Combivent Respimat$451$93,508119 claims
Lilly USA, LLCMounjaro$696$77,24561 claims
GSKTrelegy Ellipta, Breo Ellipta$15,957$71,048106 claims
MerckJanuvia$12$59,55569 claims
PfizerEliquis$20,195$55,964107 claims
AstraZenecaFarxiga, Breztri Aerosphere$290$44,14545 claims
Johnson & JohnsonXarelto$341$22,42337 claims
AbbVieLinzess$295$7,53813 claims
Astellas Pharma US IncMyrbetriq$21$4,54918 claims
NovartisEntresto$206$3,75411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →